Research programme: anti-cancer therapeutics - MicroQuin Therapeutics
Latest Information Update: 12 Sep 2024
At a glance
- Originator MicroQuin
- Class Antineoplastics
- Mechanism of Action Bcl-X protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Gynaecological cancer
- Research Lung cancer; Solid tumours
Most Recent Events
- 10 Sep 2024 Early research in Lung cancer in USA (unspecified route) prior to September 2024 (MicroQuin pipeline, September 2024)
- 10 Sep 2024 Early research in Solid tumours in USA (unspecified route) prior to September 2024 (MicroQuin pipeline, September 2024)
- 03 Sep 2021 Preclinical trials in Breast cancer in USA (unspecified route) (MicroQuin company pipeline, September 2021)